DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

World Drug Safety Congress Europe 2024 – discount of 50% 28 August 2024

It is a great pleasure to announce another partnership: World Drug Safety Congress Europe 2024, 9-10... Read more

BioEurope – get a 10% discount on registration fees! 14 August 2024

We’re delighted to share that we have partnered with BioEurope which will take place in Stockholm,... Read more

Get a 15% discount for the LSX Nordic Congress 2024! 07 August 2024

Here we go again! Another great offer for you. DANISH BIO-DANSK BIOTEK has partnered with LSX Nordic... Read more

Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators. 14 June 2024

The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10%... Read more

Nykode Therapeutics ASA: Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy 11 June 2024

Oslo, Norway, June 11, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical... Read more

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients 11 June 2024

Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing... Read more

LOPHORA SUBMITS CLINICAL TRIAL AUTHORISATION (CTA) APPLICATION TO THE FRENCH MEDICINES AGENCY (ANSM) FOR LEAD CNS DRUG LPH-5. 31 May 2024

Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines... Read more

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer 14 May 2024

Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical... Read more

Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 13 May 2024

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating... Read more

Copyright 2024 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design